• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Dr Michael Chiang: How the National Eye Institute Is Building Confidence in Ophthalmology Biosimilars


Michael Chiang, MD, director of the National Eye Institute, discusses how his team is working to instill greater confidence in ophthalmology biosimilars among wary ophthalmologists.

Finding the right people to research ophthalmology biosimilars will be critical for the National Eye Institute (NEI) to help address hesitency and mistrust in these products among ophthalmologists, said Michael Chiang, MD, director of the NEI.


What is the NEI approach to newly emerging ophthalmology biosimilars, especially as we begin to see hesitancy among retinal specialists to use biosimilars despite potential cost savings?

Chiang: This is an important question. At the National Eye Institute, our role is, basically, to identify important research studies and to support them. And hopefully, these are going to be the things that lead to advances in clinical care. With biosimilars, some of the fundamental questions are, of course, are they safe? Are they clinically effective? And are they cost-effective? And those are not exactly the same questio, and you don't study them the same way.

So, what I see as our role is, basically, we have to work with people in the community who want to study these questions, identify exactly how we're going to do them, and get the data to really answer the questions that ophthalmologists need.

Recent Videos
Jeffrey Casberg, MS, RPh
Jeffrey Casberg, RPh, MS.
Jeffrey Casbery, IPD Analytics
Lakesha Farmer, PharmD
Lakesha Farmer from Cencora
Jeffrey Casberg, RPh, MS.
Adam Colborn, JD.
Legal scale weighs profit as greater than medical treatment
Related Content
© 2024 MJH Life Sciences

All rights reserved.